February 8, 2021
Prof. Takeshi Iwatsubo, Department of Neuropathology, Graduate School of Medicine, The University of Tokyo Biogen’s controversial Alzheimer’s drug aducanumab was filed for Japanese regulatory approval in December. If approved, it will be the first disease-modifying therapy and a definite game...read more